Safety of discontinuing Cotrimoxazole Prophylaxis among African adults on ART. A randomised controlled trial
Lead Research Organisation:
University College London
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
People |
ORCID iD |
Publications
Anywaine Z
(2015)
Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP trial): Design.
in Contemporary clinical trials
Kasirye R
(2015)
Effect of cotrimoxazole prophylaxis on malaria occurrence in HIV-infected patients on antiretroviral therapy in sub-Saharan Africa.
in Tropical medicine & international health : TM & IH
Kasirye RP
(2016)
Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan adults on antiretroviral therapy: a randomised, placebo-controlled study.
in AIDS (London, England)
Nunn A
(2016)
Exit interviews administered to patients participating in the COSTOP placebo controlled randomised trial in Uganda.
in Contemporary clinical trials communications
Kasirye RP
(2017)
Effect of antiretroviral therapy on malaria incidence in HIV-infected Ugandan adults.
in AIDS (London, England)
Kyosiimire-Lugemwa J
(2020)
Effect of Stopping Cotrimoxazole Preventive Therapy on Microbial Translocation and Inflammatory Markers Among Human Immunodeficiency Virus-Infected Ugandan Adults on Antiretroviral Therapy: The COSTOP Trial Immunology Substudy.
in The Journal of infectious diseases
| Guideline Title | Consolidated Guidelines for the Prevention and Treatment of HIV and AIDS in Uganda. 2nd edition September 2018 |
| Description | Revised Cotrimoxazole prophylaxis policy in Uganda |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Routine cotrimoxazole prophylactic therapy (CPT) has been recommended since about the year 2000 to be provided to all HIV infected patients in Africa and beyond. Our research has shown that it can be safe to stop CPT once HIV infected patients have regained their immune competence due to antiretroviral therapy. In such patients, the discontinuation of CPT is associated with a decreased risk of haematological side effects due to cotrimoxazole and reduced pill burden. At the health systems level, discontinuation of CPT leads to reduced costs. The revised HIV care guidelines imply that CPT should not generally be provided to HIV infected patients, but only to certain specified high risk groups such as people whose infection is not virally supressed or to pregnant women etc. We expect that other resource restricted countries will also introduce similar policy changes. |
| Description | Training budget of the MRC Uganda Research Unit on AIDS - (1) for PhD research of Dr Ronnie Kasirye - PhD successfully completed (2013 - 2016); (2) for PhD research of Dr David Katende - PhD project ongoing (2018 - 2022) - funding value: 2 x about 36,000 |
| Amount | £72,000 (GBP) |
| Organisation | MRC/UVRI Uganda Research Unit on AIDS |
| Sector | Public |
| Country | Uganda |
| Start | 01/2018 |
| Description | Feedback MoH |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Presentation of research results from phase 1 and 2 of the award to policy makers and district health services managers in Uganda and Tanzania. Discussion of potential policy implications, and of activities for final phases of the award. Repeated contact with MoH officials and District Medical Officers in Uganda and Tanzania National NCD programme leaders and district health services managers in Uganda and Tanzania confirmed earlier committments made to collaborate closely on activities of the award. Subsequently we observed a tangible increase in the support of efforts with respect to the control of non-communicable diseases in their areas of jurisdiction. |
| Year(s) Of Engagement Activity | 2013,2014,2015 |